Achieving goals early -
effective at day 1
Keppra provides significant seizure freedom in adults on the first day of treatment
“ In hospitalized patients, a newly initiated AED with a fast onset of action might reduce the duration of hospital stay....the ability to initiate an AED at a therapeutic dose might improve compliance by eliminating complex titration schedules”
- Increase in percentage of seizure-free adult patients following treatment titration
*This analysis of treatment effect was based on
an assessment of the pooled population from 3 Phase III, randomised,
double-blind, adjunctive, placebo-controlled trials at a dose range
of 1000-3000 mg/day. The drug dose was escalated by 1000 mg/day increments
every
2 weeks, except for the 1000 mg/day group in a study where 333 mg/day
increments were used. In another study, the 1000 mg/day group
received a placebo run-in during the first 2 weeks. Keppra was started
on Day 14 after randomisation in order to reach the randomised
dose at the end of the titration period. Out of the 904 patients
included in the 3 pooled studies, 883 patients were evaluated, 576
randomised to Keppra (96 at 333 mg/day and 480 at 1000 mg/day starting
doses), and 307 to placebo.
Evidence for a rapid action of levetiracetam compared to topiramate in refractory partial epilepsy.
Specchio LM et al., Seizure. 2006 Mar;15(2):112-6. Epub 2006 Jan 6.
